Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Affymetrix: More Than Microarrays
Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes
- Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since the early 1990s, has grown to become much more than a microarray innovator. Through internal development and acquisitions, it now offers leading-edge technologies for multiplex and parallel analysis of cells, proteins, and genes to ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.